{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:47:02Z","timestamp":1740138422884,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s12020-019-02027-3","type":"journal-article","created":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T10:03:02Z","timestamp":1564653782000},"page":"550-557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["FGF21 and glycemic control in patients with T1D"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5776-0321","authenticated-orcid":false,"given":"Simone","family":"Rosell Rask","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0708-2868","authenticated-orcid":false,"given":"Troels","family":"Krarup Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5511-8829","authenticated-orcid":false,"given":"Mette","family":"Bjerre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,1]]},"reference":[{"issue":"6","key":"2027_CR1","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1172\/JCI23606","volume":"115","author":"A Kharitonenkov","year":"2005","unstructured":"A. Kharitonenkov, T.L. Shiyanova, A. Koester, A.M. Ford, R. Micanovic, E.J. Galbreath, G.E. Sandusky, L.J. Hammond, J.S. Moyers, R.A. Owens, J. Gromada, J.T. Brozinick, E.D. Hawkins, V.J. Wroblewski, D.S. Li, F. Mehrbod, S.R. Jaskunas, A.B. Shanafelt, FGF-21 as a novel metabolic regulator. J. Clin. Investig. 115(6), 1627\u20131635 (2005). \n                    https:\/\/doi.org\/10.1172\/jci23606","journal-title":"J. Clin. Investig."},{"issue":"2","key":"2027_CR2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/dom.12408","volume":"17","author":"JH Kim","year":"2015","unstructured":"J.H. Kim, K.H. Bae, Y.K. Choi, Y. Go, M. Choe, Y.H. Jeon, H.W. Lee, S.H. Koo, J.W. Perfield 2nd, R.A. Harris, I.K. Lee, K.G. Park, Fibroblast growth factor 21 analogue LY2405319 lowers blood glucose in streptozotocin-induced insulin-deficient diabetic mice by restoring brown adipose tissue function. Diabetes Obes. Metab. 17(2), 161\u2013169 (2015). \n                    https:\/\/doi.org\/10.1111\/dom.12408","journal-title":"Diabetes Obes. Metab."},{"key":"2027_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ejphar.2015.07.003","volume":"764","author":"B Andersen","year":"2015","unstructured":"B. Andersen, B.A. Omar, G. Rakipovski, K. Raun, B. Ahren, Fibroblast growth factor 21 prevents glycemic deterioration in insulin deficient mouse models of diabetes. Eur. J. Pharmacol. 764, 189\u2013194 (2015). \n                    https:\/\/doi.org\/10.1016\/j.ejphar.2015.07.003","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"2027_CR4","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jdiacomp.2017.01.008","volume":"31","author":"X Ye","year":"2017","unstructured":"X. Ye, J. Qi, D. Yu, Y. Wu, S. Zhu, S. Li, Q. Wu, G. Ren, D. Li, Pharmacological efficacy of FGF21 analogue, liraglutide, and insulin glargine in treatment of type 2 diabetes. J. Diabetes Complicat. 31(4), 726\u2013734 (2017). \n                    https:\/\/doi.org\/10.1016\/j.jdiacomp.2017.01.008","journal-title":"J. Diabetes Complicat."},{"issue":"11","key":"2027_CR5","doi-asserted-by":"publisher","first-page":"5986","DOI":"10.1074\/jbc.M115.710582","volume":"291","author":"DR Dunshee","year":"2016","unstructured":"D.R. Dunshee, T.W. Bainbridge, N.M. Kljavin, J. Zavala-Solorio, A.C. Schroeder, R. Chan, R. Corpuz, M. Wong, W. Zhou, G. Deshmukh, J. Ly, D.P. Sutherlin, J.A. Ernst, J. Sonoda, Fibroblast activation protein cleaves and inactivates fibroblast growth factor 21. J. Biol. Chem. 291(11), 5986\u20135996 (2016). \n                    https:\/\/doi.org\/10.1074\/jbc.M115.710582","journal-title":"J. Biol. Chem"},{"issue":"2","key":"2027_CR6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/jcp.21675","volume":"219","author":"R Micanovic","year":"2009","unstructured":"R. Micanovic, D.W. Raches, J.D. Dunbar, D.A. Driver, H.A. Bina, C.D. Dickinson, A. Kharitonenkov, Different roles of N- and C- termini in the functional activity of FGF21. J. Cell. Physiol. 219(2), 227\u2013234 (2009). \n                    https:\/\/doi.org\/10.1002\/jcp.21675","journal-title":"J. Cell. Physiol."},{"issue":"1","key":"2027_CR7","doi-asserted-by":"publisher","first-page":"E54","DOI":"10.1210\/jc.2011-1930","volume":"97","author":"Y Xiao","year":"2012","unstructured":"Y. Xiao, A. Xu, L.S. Law, C. Chen, H. Li, X. Li, L. Yang, S. Liu, Z. Zhou, K.S. Lam, Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes. J. Clin. Endocrinol. Metab. 97(1), E54\u2013E58 (2012). \n                    https:\/\/doi.org\/10.1210\/jc.2011-1930","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"2027_CR8","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1007\/s12020-014-0413-9","volume":"48","author":"K Zibar","year":"2015","unstructured":"K. Zibar, K. Blaslov, T. Bulum, J.K. Cuca, L. Smircic-Duvnjak, Basal and postprandial change in serum fibroblast growth factor-21 concentration in type 1 diabetic mellitus and in healthy controls. Endocrine 48(3), 848\u2013855 (2015). \n                    https:\/\/doi.org\/10.1007\/s12020-014-0413-9","journal-title":"Endocrine"},{"issue":"3","key":"2027_CR9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrd2792","volume":"8","author":"A Beenken","year":"2009","unstructured":"A. Beenken, M. Mohammadi, The FGF family: biology, pathophysiology and therapy. Nat. Rev. Drug Discov. 8(3), 235\u2013253 (2009). \n                    https:\/\/doi.org\/10.1038\/nrd2792","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"2027_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022976","volume":"6","author":"T Uebanso","year":"2011","unstructured":"T. Uebanso, Y. Taketani, H. Yamamoto, K. Amo, H. Ominami, H. Arai, Y. Takei, M. Masuda, A. Tanimura, N. Harada, H. Yamanaka-Okumura, E. Takeda, Paradoxical regulation of human FGF21 by both fasting and feeding signals: is FGF21 a nutritional adaptation factor? PLoS ONE 6(8), e22976 (2011). \n                    https:\/\/doi.org\/10.1371\/journal.pone.0022976","journal-title":"PLoS ONE"},{"issue":"1","key":"2027_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.molmet.2014.09.008","volume":"4","author":"JR Dushay","year":"2015","unstructured":"J.R. Dushay, E. Toschi, E.K. Mitten, F.M. Fisher, M.A. Herman, E. Maratos-Flier, Fructose ingestion acutely stimulates circulating FGF21 levels in humans. Mol. Metab. 4(1), 51\u201357 (2015). \n                    https:\/\/doi.org\/10.1016\/j.molmet.2014.09.008","journal-title":"Mol. Metab."},{"issue":"1","key":"2027_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.molmet.2016.11.001","volume":"6","author":"AM Lundsgaard","year":"2017","unstructured":"A.M. Lundsgaard, A.M. Fritzen, K.A. Sjoberg, L.S. Myrmel, L. Madsen, J.F.P. Wojtaszewski, E.A. Richter, B. Kiens, Circulating FGF21 in humans is potently induced by short term overfeeding of carbohydrates. Mol. Metab. 6(1), 22\u201329 (2017). \n                    https:\/\/doi.org\/10.1016\/j.molmet.2016.11.001","journal-title":"Mol. Metab."},{"issue":"1","key":"2027_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1530\/EC-16-0103","volume":"6","author":"ES Lauritzen","year":"2017","unstructured":"E.S. Lauritzen, N. Rittig, E. Bach, N. Moller, M. Bjerre, LPS infusion suppresses serum FGF21 levels in healthy adult volunteers. Endocr. Connect. 6(1), 39\u201343 (2017). \n                    https:\/\/doi.org\/10.1530\/ec-16-0103","journal-title":"Endocr. Connect."},{"issue":"9","key":"2027_CR14","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1007\/s00125-005-1850-z","volume":"48","author":"J Frystyk","year":"2005","unstructured":"J. Frystyk, L. Tarnow, T.K. Hansen, H.H. Parving, A. Flyvbjerg, Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 48(9), 1911\u20131918 (2005). \n                    https:\/\/doi.org\/10.1007\/s00125-005-1850-z","journal-title":"Diabetologia"},{"issue":"9","key":"2027_CR15","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.2337\/db05-1435","volume":"55","author":"W Wente","year":"2006","unstructured":"W. Wente, A.M. Efanov, M. Brenner, A. Kharitonenkov, A. Koster, G.E. Sandusky, S. Sewing, I. Treinies, H. Zitzer, J. Gromada, Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1\/2 and Akt signaling pathways. Diabetes 55(9), 2470\u20132478 (2006). \n                    https:\/\/doi.org\/10.2337\/db05-1435","journal-title":"Diabetes"},{"issue":"5","key":"2027_CR16","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1053\/j.gastro.2009.07.064","volume":"137","author":"CL Johnson","year":"2009","unstructured":"C.L. Johnson, J.Y. Weston, S.A. Chadi, E.N. Fazio, M.W. Huff, A. Kharitonenkov, A. Koester, C.L. Pin, Fibroblast growth factor 21 reduces the severity of cerulein-induced pancreatitis in mice. Gastroenterology 137(5), 1795\u20131804 (2009). \n                    https:\/\/doi.org\/10.1053\/j.gastro.2009.07.064","journal-title":"Gastroenterology"},{"issue":"5","key":"2027_CR17","doi-asserted-by":"publisher","first-page":"974","DOI":"10.2337\/db17-0830","volume":"67","author":"Z Fu","year":"2018","unstructured":"Z. Fu, Z. Wang, C.H. Liu, Y. Gong, B. Cakir, R. Liegl, Y. Sun, S.S. Meng, S.B. Burnim, I. Arellano, E. Moran, R. Duran, A. Poblete, S.S. Cho, S. Talukdar, J.D. Akula, A. Hellstrom, L.E.H. Smith, Fibroblast growth factor 21 protects photoreceptor function in Type 1 diabetic mice. Diabetes 67(5), 974\u2013985 (2018). \n                    https:\/\/doi.org\/10.2337\/db17-0830","journal-title":"Diabetes"},{"issue":"2","key":"2027_CR18","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1172\/JCI67353","volume":"124","author":"B Emanuelli","year":"2014","unstructured":"B. Emanuelli, S.G. Vienberg, G. Smyth, C. Cheng, K.I. Stanford, M. Arumugam, M.D. Michael, A.C. Adams, A. Kharitonenkov, C.R. Kahn, Interplay between FGF21 and insulin action in the liver regulates metabolism. J. Clin. Investig. 124(2), 515\u2013527 (2014). \n                    https:\/\/doi.org\/10.1172\/jci67353","journal-title":"J. Clin. Investig."},{"issue":"10","key":"2027_CR19","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.1210\/jc.2017-01257","volume":"102","author":"RJ Samms","year":"2017","unstructured":"R.J. Samms, J.E. Lewis, L. Norton, F.B. Stephens, C.J. Gaffney, T. Butterfield, D.P. Smith, C.C. Cheng, J.W. Perfield 2nd, A.C. Adams, F.J.P. Ebling, K. Tsintzas, FGF21 is an insulin-dependent postprandial hormone in adult humans. J. Clin. Endocrinol. Metab. 102(10), 3806\u20133813 (2017). \n                    https:\/\/doi.org\/10.1210\/jc.2017-01257","journal-title":"J. Clin. Endocrinol. Metab"},{"issue":"10","key":"2027_CR20","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1515\/jpem-2016-0139","volume":"29","author":"RP Hoffman","year":"2016","unstructured":"R.P. Hoffman, A.S. Dye, H. Huang, J.A. Bauer, Glycemic variability predicts inflammation in adolescents with type 1 diabetes. J. Pediatr. Endocrinol. Metab. 29(10), 1129\u20131133 (2016). \n                    https:\/\/doi.org\/10.1515\/jpem-2016-0139","journal-title":"J. Pediatr. Endocrinol. Metab."},{"issue":"1","key":"2027_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.diabres.2011.02.034","volume":"93","author":"X Li","year":"2011","unstructured":"X. Li, X. Fan, F. Ren, Y. Zhang, C. Shen, G. Ren, J. Sun, N. Zhang, W. Wang, G. Ning, J. Yang, Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently. Diabetes Res. Clin. Pract. 93(1), 10\u201316 (2011). \n                    https:\/\/doi.org\/10.1016\/j.diabres.2011.02.034","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"3","key":"2027_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151269","volume":"11","author":"AL Coppage","year":"2016","unstructured":"A.L. Coppage, K.R. Heard, M.T. DiMare, Y. Liu, W. Wu, J.H. Lai, W.W. Bachovchin, Human FGF-21 is a substrate of fibroblast activation protein. PLoS ONE 11(3), e0151269 (2016). \n                    https:\/\/doi.org\/10.1371\/journal.pone.0151269","journal-title":"PLoS ONE"},{"issue":"1","key":"2027_CR23","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jdiacomp.2016.08.022","volume":"31","author":"L Duvnjak","year":"2017","unstructured":"L. Duvnjak, M.N. Perkovic, K. Blaslov, Dipeptidyl peptidase-4 activity is associated with urine albumin excretion in type 1 diabetes. J. Diabetes Complicat. 31(1), 218\u2013222 (2017). \n                    https:\/\/doi.org\/10.1016\/j.jdiacomp.2016.08.022","journal-title":"J. Diabetes Complicat."},{"issue":"1","key":"2027_CR24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jdiacomp.2016.10.017","volume":"31","author":"CH Jung","year":"2017","unstructured":"C.H. Jung, S.H. Jung, B.Y. Kim, C.H. Kim, S.K. Kang, J.O. Mok, The U-shaped relationship between fibroblast growth factor 21 and microvascular complication in type 2 diabetes mellitus. J. Diabetes Complicat. 31(1), 134\u2013140 (2017). \n                    https:\/\/doi.org\/10.1016\/j.jdiacomp.2016.10.017","journal-title":"J. Diabetes Complicat."},{"issue":"12","key":"2027_CR25","doi-asserted-by":"publisher","first-page":"4886","DOI":"10.1210\/jc.2016-2308","volume":"101","author":"Q Li","year":"2016","unstructured":"Q. Li, Y. Zhang, D. Ding, Y. Yang, Q. Chen, D. Su, X. Chen, W. Yang, J. Qiu, W. Ling, Association between serum fibroblast growth factor 21 and mortality among patients with coronary artery disease. J. Clin. Endocrinol. Metab. 101(12), 4886\u20134894 (2016). \n                    https:\/\/doi.org\/10.1210\/jc.2016-2308","journal-title":"J. Clin. Endocrinol. Metab"},{"issue":"2","key":"2027_CR26","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.diabres.2013.04.010","volume":"101","author":"M Lenart-Lipinska","year":"2013","unstructured":"M. Lenart-Lipinska, B. Matyjaszek-Matuszek, W. Gernand, A. Nowakowski, J. Solski, Serum fibroblast growth factor 21 is predictive of combined cardiovascular morbidity and mortality in patients with type 2 diabetes at a relatively short-term follow-up. Diabetes Res. Clin. Pract. 101(2), 194\u2013200 (2013). \n                    https:\/\/doi.org\/10.1016\/j.diabres.2013.04.010","journal-title":"Diabetes Res. Clin. Pract."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-019-02027-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-019-02027-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-019-02027-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:04:59Z","timestamp":1596153899000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-019-02027-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["2027"],"URL":"https:\/\/doi.org\/10.1007\/s12020-019-02027-3","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"type":"print","value":"1355-008X"},{"type":"electronic","value":"1559-0100"}],"subject":[],"published":{"date-parts":[[2019,8,1]]},"assertion":[{"value":"21 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of The Central Denmark Region Committees on Health Research Ethics (1-10-72-255-15) and of the Danish Data Protection Agency (1-16-02-83-16) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}